Cargando…

Satisfactory virological response and fibrosis improvement of sofosbuvir-based regimens for Chinese patients with hepatitis C virus genotype 3 infection: results of a real-world cohort study

BACKGROUND: Chronic hepatitis C virus (HCV) genotype (GT) 3 infection with advanced liver disease has emerged as a challenging to treat by direct-acting antivirals (DAAs), but the efficacy of DAAs in Chinese HCV-GT3 patients is rarely reported. This study aimed to analyze the efficacy of sofosbuvir...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tao, Ya-Chao, Deng, Rong, Wang, Meng-Lan, Lv, Duo-Duo, Yuan, Man, Wang, Yong-Hong, Chen, En-Qiang, Tang, Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167801/ https://www.ncbi.nlm.nih.gov/pubmed/30285800 http://dx.doi.org/10.1186/s12985-018-1066-8

Ejemplares similares

Sofosbuvir-Based Therapies Achieved Satisfactory Virological Response in Chinese Individuals with Genotypes 3 and 6 Infections: A Real-World Experience
por: Tang, Qiao, et al.
Publicado: (2021)

High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world setting
por: Han, Qunying, et al.
Publicado: (2019)

Sofosbuvir-based regimen for genotype 2 HCV infected patients in Taiwan: A real world experience
por: Tsai, Wei-Lun, et al.
Publicado: (2020)

Real-World Single-Center Experience with Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C Genotype 1 Patients
por: Shin, Hyun Phil, et al.
Publicado: (2017)

Real-World Virological Efficacy and Safety of Ledipasvir and Sofosbuvir in Patients with Chronic Hepatitis C Virus Genotype 2 Infection: A Multicenter Study
por: Tada, Toshifumi, et al.
Publicado: (2020)

Outcomes after sofosbuvir-containing regimens for hepatitis C virus in patients with decompensated cirrhosis: a real-world study
por: Ji, Fanpu, et al.
Publicado: (2017)

Efficacy and safety of sofosbuvir-based pangenotypic direct-acting antiviral agents for chronic hepatitis C patients without genotype determination: Real-world experience of a retrospective study
por: Li, Juan, et al.
Publicado: (2020)

Effectiveness of sofosbuvir based direct-acting antiviral regimens for chronic hepatitis C virus genotype 6 patients: Real-world experience in Vietnam
por: Nguyen, Dung Thanh, et al.
Publicado: (2020)

The predictors of sustained virological response with sofosbuvir and ribavirin in patients with chronic hepatitis C genotype 2
por: Han, Sung Yong, et al.
Publicado: (2021)

Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan
por: Mushtaq, Saima, et al.
Publicado: (2020)

Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin
por: Kanda, Tatsuo, et al.
Publicado: (2017)

Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand
por: Sirinawasatien, Apichet, et al.
Publicado: (2020)

Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium
por: Degré, Delphine, et al.
Publicado: (2017)

Peripheral blood correlates of virologic relapse after Sofosbuvir and Ribavirin treatment of Genotype-1 HCV infection
por: Orr, Cody, et al.
Publicado: (2020)

Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure
por: Mir, Fazia, et al.
Publicado: (2017)

Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan
por: Liu, Chen-Hua, et al.
Publicado: (2018)

Clinical, Virological Characteristics, and Outcomes of Treatment with Sofosbuvir/Ledipasvir in Two Pediatric Patients Infected by HCV Genotype 4
por: Marascio, Nadia, et al.
Publicado: (2019)

Real‐world safety and efficacy of sofosbuvir and ledipasvir for elderly patients
por: Tamai, Hideyuki, et al.
Publicado: (2018)

Safety and Efficacy of Sofosbuvir with Ribavirin® in Hepatitis C, Genotype 3 Patients with Cirrhosis: A Real-world Experience
por: Butt, Nazish, et al.
Publicado: (2019)

Cost-Effectiveness Analysis of Pan-Genotypic Sofosbuvir-Based Regimens for Treatment of Chronic Hepatitis C Genotype 1 Infection in China
por: Zhou, Hui Jun, et al.
Publicado: (2021)

Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany
por: Buggisch, Peter, et al.
Publicado: (2019)

Real‐world treatment outcomes of sofosbuvir‐based regimens for treatment of chronic hepatitis C with and without human immunodeficiency virus co‐infection
por: Khemnark, Suparat, et al.
Publicado: (2023)

Sofosbuvir/velpatasvir is an effective treatment for patients with hepatitis C and advanced fibrosis or cirrhosis in a real-world setting in Taiwan
por: Huang, Yu-Ting, et al.
Publicado: (2021)

Effect of Health Insurance on Hepatitis C Sustained Virologic Response Rates to Sofosbuvir-Based Treatment Regimens in a South Florida Community Hospital
por: Eckardt, Paula, et al.
Publicado: (2019)

Sofosbuvir-Based Therapies for Patients with Hepatitis C Virus Infection: Real-World Experience in China
por: Hu, Chengguang, et al.
Publicado: (2018)

Achieving the Sustained Virologic Response With a Short-Course Treatment of Sofosbuvir/Velpatasvir
por: Abi-Saleh, Simon P, et al.
Publicado: (2023)

Real-World Experience with Coformulated Ledipasvir and Sofosbuvir for HIV-Positive Patients with HCV Genotype 2 Infection: A Multicenter, Retrospective Study
por: Liou, Bo-Huang, et al.
Publicado: (2021)

Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort
por: Welzel, Tania M, et al.
Publicado: (2016)

Incidence of Hepatocellular Carcinoma after Treatment with Sofosbuvir-Based or Sofosbuvir-Free Regimens in Patients with Chronic Hepatitis C
por: Ogawa, Eiichi, et al.
Publicado: (2020)

Virological Failure and Acquired Genotypic Resistance Associated With Contemporary Antiretroviral Treatment Regimens
por: Rhee, Soo-Yon, et al.
Publicado: (2020)

Effect of silibinin capsules combined with lifestyle modification on hepatic steatosis in patients with chronic hepatitis B
por: Lv, Duo-Duo, et al.
Publicado: (2021)

Real-world effectiveness of sofosbuvir plus ribavirin for chronic hepatitis C genotype 2 in Asia: a systematic review and meta-analysis
por: Wei, Bin, et al.
Publicado: (2018)

Erratum: Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort
Publicado: (2016)

Rapid virological&End treatment response of patients treated with Sofosbuvir in Chronic Hepatitis C
por: Siddique, Muhammad Shoaib, et al.
Publicado: (2017)

Efficacy of 8- versus 12-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8-week regimen in a real-world setting
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2019)

Sofosbuvir in combination with ribavirin or simeprevir: real-life study of patients with hepatitis C genotype 4
por: Abdel-Moneim, Adel, et al.
Publicado: (2019)

Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study
por: Welzel, Tania M, et al.
Publicado: (2017)

Daclatasvir plus Sofosbuvir with or without ribavirin in patients with chronic Hepatitis C genotype 3a in Pakistani population - A real world experience
por: Butt, Zamir, et al.
Publicado: (2019)

Efficacy and safety of sofosbuvir-based regimens for treatment in chronic hepatitis C genotype 1 patients with moderately impaired renal function
por: Shin, Hyun Phil, et al.
Publicado: (2017)

Three regimens for re-treatment failure of Sofosbuvir-based therapy for chronic hepatitis-C genotype-4: a cohort study
por: Shousha, Hend Ibrahim, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_miuemim4v2969l4ubb3rvf2t48